Hope for a deadly disease: first trial tests pill to halt brain damage
NCT ID NCT06923072
Summary
This study is testing whether a pill called baricitinib can slow or stop the progression of brain and spine lesions in people with Kohlmeier-Degos disease, a rare and often fatal condition that causes blockages in small blood vessels. Twelve adults with neurological involvement from the disease will take the drug daily for 24 weeks while continuing their current medications, to see if it stabilizes their brain scans and improves their quality of life. The goal is to control the disease, as there is currently no approved treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KOHLMEIER-DEGOS DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.